Embecta

Embecta FCF Growth

The Year-over-Year Free Cash Flow Growth of Embecta (EMBC) as of Nov 21, 2026 is 816.58 %. In the previous year, Year-over-Year Free Cash Flow Growth was -51.70 % — a change of -1,679.49% (higher).

FCF Growth

816.58 %

YoY

-1,679.49%

Last updated:

Year-over-Year Free Cash Flow Growth of Embecta is 2025 816.58 % . Year-over-Year Free Cash Flow Growth of Embecta was 2024 -51.70 % . It decreases by -1,679.49% higher compared to the previous year.

The Embecta FCF Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Growth
Date
FCF Growth
Jan 1, 2020
4.72 USD
Jan 1, 2021
-8.67 USD
Jan 1, 2022
-6.91 USD
Jan 1, 2023
-89.39 USD
Jan 1, 2024
-51.70 USD
Jan 1, 2025
816.58 USD
The Embecta FCF Growth history
YEARFCF GrowthYoY
816.58 %-1,679.49%
-51.70 %-42.16%
-89.39 %+1,194.25%
-6.91 %-20.37%
-8.67 %-283.56%
4.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta Stock analysis

What does Embecta do? Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management. Embecta is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Embecta stock

Year-over-Year Free Cash Flow Growth of Embecta is 816.58 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Free Cash Flow Growth Embecta since 2006 – with annual values, charts, and detailed analysis.

FCF growth measures the percentage change in free cash flow. Growing FCF indicates improving cash generation capability.

To evaluate Year-over-Year Free Cash Flow Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Free Cash Flow Growth.

Year-over-Year Free Cash Flow Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Free Cash Flow Growth's Embecta historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Embecta

All Key Metrics — Embecta